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Abstract
Background.—Surveillance data from a large measles outbreak in Mongolia suggested 
increased case fatality ratio (CFR) in the second of 2 waves. To confirm the increase in CFR and 
identify risk factors for measles death, we enhanced mortality ascertainment and conducted a case-
control study among infants hospitalized for measles.
Methods.—We linked national vital records with surveillance data of clinically or laboratory-
confirmed infant (aged <12 months) measles cases with rash onset during March–September 2015 
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(wave 1) and October 2015–June 2016 (wave 2). We abstracted medical charts of 95 fatal cases 
and 273 nonfatal cases hospitalized for measles, matched by age and sex. We calculated adjusted 
matched odds ratios (amORs) and 95% confidence intervals (CIs) for risk factors.
Results.—Infant measles deaths increased from 3 among 2224 cases (CFR: 0.13%) in wave 1 to 
113 among 4884 cases (CFR: 2.31%) in wave 2 (P < .001). Inpatient admission, 7–21 days before 
measles rash onset, for pneumonia or influenza (amOR: 4.5; CI, 2.6–8.0), but not other diagnoses, 
was significantly associated with death.
Discussion.—Measles infection among children hospitalized with respiratory infections likely 
increased deaths due to measles during wave 2. Preventing measles virus nosocomial transmission 
likely decreases measles mortality.
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Measles virus is a paramyxovirus of the genus Morbillivirus transmitted from person to 
person by droplet or aerosolized respiratory fluids of measles virus-infected persons [1]. The 
incubation period is 7–21 days; signs and symptoms of measles include fever, generalized 
maculopapular erythematous rash, cough, coryza, and conjunctivitis. Common measles 
complications include pneumonia, otitis media, thrombocytopenia, diarrhea, and 
encephalitis. Measles can lead to death or disability including blindness, deafness, or 
intellectual disabilities associated with encephalitis [2].
Despite the availability of a safe and highly effective vaccine, measles remains a leading 
cause of under-5 mortality [3]. Measles mortality can be underreported to routine 
surveillance systems, as the death often occurs weeks after the initial report of the case or 
after a case has been discharged from the hospital. Independent risk factors for measles 
mortality include age <3 years, neurological complications, lack of measles vaccination, lack 
of receiving a full course of vitamin A for case management, and exposure in the household 
[1, 4–6].
In Mongolia, measles-containing vaccine (MCV) administered at 9 months of age was 
introduced into the national Expanded Programme on Immunization (EPI) in 1973, and a 
second dose given at 2 years of age was introduced in 1989. Following increasing 
vaccination coverage, no cases of measles were reported during 2011–2014. Mongolia was 
certified measles free by the World Health Organization (WHO) Western Pacific Regional 
Verification Commission in July 2014 [7].
Beginning in March 2015, a large nationwide measles outbreak began, with 49 908 
suspected cases reported during March 2015–June 2016. The outbreak was the largest 
documented measles outbreak in any setting after verification of measles elimination. 
Measles virus transmission occurred during 2 waves: March– September 2015 (wave 1) [8] 
and October 2015–June 2016 (wave 2). Surveillance data suggested increased infant 
mortality during the second versus the first wave, although it was unclear whether this 
difference was due to reporting or detection bias, the population affected, clinical care or 
delays to clinical care among rural populations, or other factors. Because of the apparent 
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increase in mortality among infants, we sought to verify the increase in mortality and case 
fatality ratio (CFR) by enhancing death ascertainment of confirmed infant measles cases and 
to identify independent risk factors for infant measles mortality during the second wave 
using a matched case-control study.
METHODS
Participants and Data Collection
We analyzed case-based surveillance data reported from health care providers and collected 
by the national EPI program during March 2015–June 2016. We restricted analyses to 
confirmed measles cases among persons with laboratory evidence of measles virus infection 
(ie, presence of measles immunoglobulin-M [IgM] by enzyme linked immunosorbent assay 
or detection of measles RNA by reverse transcriptase polymerase chain reaction [RT-PCR]) 
or clinical evidence of infection (ie, presence of fever and maculopapular rash, and ≥1 of 
cough, coryza, or conjunctivitis). We also analyzed surveillance data from the Mongolia 
National Influenza Center (MNIC) on nationwide influenza-like illness hospitalizations 
among infants to ascertain when the influenza season among infants occurred, and analyzed 
MNIC influenza subtype data using real-time RT-PCR from sentinel sites during the same 
period.
We defined an infant measles death as a death that occurred <30 days of rash onset in a 
confirmed measles patient <12 months of age, without another unrelated cause (eg, trauma) 
[9]. To enhance ascertainment of measles deaths, we matched case-based surveillance data 
with national vital statistics data routinely collected by the National Center for Health 
Development with corresponding International Classification of Diseases, 10th Revision 
(ICD-10) codes of infant deaths that occurred during 2015–2016, using a probabilistic 
record linkage algorithm described elsewhere [10]. Databases were matched on name, sex, 
date of birth, and national registration number. All matches were manually confirmed.
We conducted a matched case-control study among hospitalized measles cases to identify 
risk factors associated with infant measles death. Cases were defined as fatal measles cases 
among the population of hospitalized confirmed infant measles cases with rash onset during 
the second wave (ie, 1 October 2015–27 June 2016) for whom we could locate medical 
records (Figure 1); controls were nonfatal measles cases drawn from the same population. 
Target sample size (100 cases matched with 300 controls) was calculated to detect a 
minimum odds ratio of 2.0, power of 0.80, prespecified alpha 0.05, assuming correlation 
coefficient (ϕ) between the exposure status of the ith pair of the case and control of 0.2 and 
prevalence of the risk factor among controls of 0.4. We obtained medical records for 95 
(84%) of 106 measles deaths and matched them 3:1 with 273 controls on sex and birth week.
This public health response was determined not to be human subjects’ research by the US 
Centers for Disease Control and Prevention (CDC) and the Mongolia National Center for 
Communicable Diseases.
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Medical Record Abstraction
Abstraction variables included demographic and anthropometric variables (date of birth, sex, 
Aimag [province] and Soum [district] of residence, weight, length); details on illness history 
(date of rash onset, signs and symptoms, preceding episodes of inpatient and outpatient care, 
Aimag and Soum of measles hospitalization); vaccination status as documented in the 
medical chart (MCV, pentavalent conjugate vaccine); underlying medical conditions before 
measles hospitalization; and treatment received after rash onset (intubation/mechanical 
ventilation, antibiotics, vitamin A, steroids). The tool was developed in English, translated to 
Mongolian, and independently back-translated. When autopsy results from the Mongolia 
National Pathology Center were available for review, we abstracted findings from diagnostic 
histopathological examination of formalin-fixed paraffin-embedded lung tissue, which was 
stained in all cases using hematoxylin and eosin and Lillie-Twort tissue Gram stains. Tissue 
sample RNA from a subset of 6 fatal laboratory-confirmed infant measles cases was 
extracted from FTA cards using the QIamp viral RNA mini kit (Qiagen) as described 
previously [11]. The presence of measles RNA was confirmed in all 6 samples by measles 
real-time RT-PCR [12]. The samples were tested for influenza A and B using CDC real-time 
RT-PCR assays. Any influenza A or B positive specimens were further characterized by 
subtypes and/or genotypes.
Surveillance Database Analysis
Data analysis was performed using Stata v15.0 (College Station, TX). Differences in 
proportions during wave 1 versus wave 2 were compared by Pearson Chi [2] (χ2) test.
Case-Control Analysis
Low weight-for-age was calculated as a dichotomous variable using the WHO 2006 Growth 
Standards for child weight-forage less than −2 Z-scores [13]. We created a malnutrition 
variable combining patients with low weight-for-age with those with a clinical diagnosis of 
malnutrition. Health care-associated measles infection (HAI) was defined as a confirmed 
measles case with history of any hospitalization 7–21 days before measles rash onset 
(incubation period). We created dummy variables for measles HAI for a pneumonia or 
influenza hospitalization, measles HAI for other type of hospitalization (ie, diarrheal 
disease, upper respiratory tract infection, urinary tract infection, meningitis, or other), and 
non-HAI (ie, no history of hospitalization in the 7–21 days before rash onset). We calculated 
matched odds ratios using conditional logistic regression to compare discordant pairs of 
matched cases and controls adjusted for age and sex for bivariate associations. Model 
selection was performed by comparing nested multivariable models using Akaike’s 
Information Criterion (AIC), a measure of log likelihood and variable parsimony. Variables 
collinear with the outcome (ie, intensive care unit admission, intubation/mechanical 
ventilation) were excluded from the model. Residence in Ulaanbaatar was collinear with first 
measles hospitalization in Ulaanbaatar (ie, all residents of Ulaanbaatar were hospitalized in 
Ulaanbaatar; n = 17 patients from outside of Ulaanbaatar were hospitalized in Ulaanbaatar), 
so the variable was not included in the model. We compared a base model, adjusted for age, 
sex, underlying medical conditions, and history of hospitalization (AIC 332.4) with a model 
that additionally adjusted for receipt of medical interventions, including vitamin A, 
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antibiotics, and corticosteroids (AIC 290.2). The second model demonstrated superior fit and 
was selected as the final model. We found no improvement in model fit by including history 
of breastfeeding or interaction terms. We used an n-fold cross validation of the final model 
to assess goodness of fit and found that the model performed well to classify the full data 
(86%) and test data (83%). We calculated adjusted matched odds ratios (amOR) to measure 
multivariable associations and corresponding 95% confidence intervals (CI).
RESULTS
Descriptive Epidemiology
A total of 33 947 confirmed measles cases were reported during the outbreak; 14 010 (41%) 
during wave 1 and 19 937 (59%) during wave 2 (Figure 2A). The cumulative incidence was 
11 581 per million. There were several differences in the epidemiology of the 2 outbreak 
waves. During the first wave, 9671 (69%; average weekly incidence [AWI] 153 per million) 
cases occurred among adults ≥15 years and 2224 (16%; AWI 1094 per million) cases 
occurred among infants. During the second wave, 11 346 (57%; AWI 138 per million) cases 
occurred among adults and 4884 (25%; AWI 1850 per million) cases occurred among 
infants. Whereas the majority (12 717, 91%) of cases during wave 1 occurred in 
Ulaanbaatar, in wave 2, approximately half (9258, 46%) occurred in outlying Aimags 
(Figure 2B). There was a significant increase in the proportion of HAI cases, from 2% (n = 
331) during wave 1 to 5% (n = 924) in wave 2 (χ2 P < .001) (Figure 2C). The number of 
total reported deaths increased from wave 1 (n = 3, CFR 0.02%) to wave 2 (n = 113, CFR 
0.57%) (Figure 2D). Of the 116 deaths, 97 (84%) occurred among infants. The infant CFR 
increased, from 0.04% in wave 1 to 1.97% in wave 2 (χ2 P < .001; Table 1). The second 
wave of the outbreak coincided with the seasonal influenza period (Figure 2E), with 
influenza B as the predominant circulating strain (Supplementary Figure 1).
Enhanced Infant Measles Mortality Ascertainment and Estimation of Case Fatality Ratio
Using linkage of case-based surveillance and vital statistics data, we identified 2 additional 
infant deaths in wave 1 and 17 additional deaths in wave 2 (Table 1). We calculated CFR 
using the enhanced mortality data; we identified an increase in CFR from wave 1 (0.13%) to 
wave 2 (2.31%; P < .001). Of 96 records with ICD-10 codes assigned, 86 (89.5%) of infant 
measles deaths were assigned an ICD-10 code for measles death, and 9 (9.5%) were 
assigned pneumonia (unspecified) ICD-10 codes.
Case-Control Sample Characteristics and Bivariate Analyses
Fatal cases and hospitalized controls were well matched; there were no significant 
differences between cases and controls for age at rash onset or sex (Table 2). A higher 
proportion of cases (67%) than nonfatal hospitalized controls (46%) resided in outlying 
Aimags. Most (316/368) of the cases and controls were too young to receive the first routine 
dose of MCV. Receipt of ≥1 dose of MCV was low overall, and did not significantly differ 
between cases (5%) and controls (2%). Comorbid medical conditions including premature 
birth or birth defects, immune deficiencies, rickets, malnutrition, and anemia were all 
statistically significantly more common among cases than controls (Table 2). Cases were 
more likely to have been admitted to a hospital during the measles incubation period (ie, 
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measles virus HAI) than controls (53% versus 26%; χ2 P < .001) and were more likely to be 
admitted for pneumonia or influenza diagnoses (86% of hospitalizations) than controls 
(61%; χ2 P < .001). However, the proportion of antecedent hospitalizations for other 
diagnoses (eg, urinary tract infection, diarrhea, upper respiratory infections) did not differ 
between groups. The mean duration of hospitalization was 25 days (range 9‒68) and did not 
differ significantly between cases and controls. The mean duration between hospital 
admission and rash onset was 14 days (range 8‒21). There was no difference in delay to 
hospitalization after rash onset; most cases (69%) and controls (63%) were hospitalized <2 
days after rash onset. A higher proportion of cases (64%) than controls (43%) were 
hospitalized for measles in Aimags versus Ulaanbaatar (χ2 P < .001). There were no 
significant differences in receipt of vitamin A among cases (17%) versus controls (22%). 
Case patients were less likely to receive a dose of antibiotics in the hospital (95%) than 
controls (99%; χ2 P = .02).
Multivariable Conditional Logistic Regression
After adjustment for covariates, underlying medical conditions, including premature birth or 
birth defects, immune deficiencies, rickets, and anemia were significantly associated with 
measles death (Table 3). First hospitalization after rash onset outside of Ulaanbaatar was 
significantly associated with measles death (amOR 2.5; CI, 1.1–5.8). In a sensitivity analysis 
conducted by including residence within or outside of Ulaanbaatar as a predictor variable, 
hospitalization outside of Ulaanbaatar and not residence outside of Ulaanbaatar was 
significantly associated with measles death (data not shown). Compared with infants who 
were not hospitalized during the measles incubation period, infants admitted during the 
incubation period with pneumonia or influenza diagnosis (amOR 4.5; CI, 1.9–10.8) were 
more likely to die whereas those admitted for other diagnoses (amOR 0.7; CI, 0.2–2.7) were 
not.
Clinical and Diagnostic Findings
A higher proportion of fatal cases (91/95, 96%) than hospitalized controls (182/273, 67%) 
had clinical pneumonia diagnoses in the chart, and a higher proportion of fatal cases (19/95, 
20%) than hospitalized controls (1/273, 0.4%) were diagnosed with acute respiratory distress 
syndrome (Table 4). Influenza A or B testing results were not identified in any charts. Fatal 
cases were more likely to have neurologic complications than hospitalized controls, 
including encephalitis, meningitis, and seizure. Autopsy was performed on a subset (n = 10) 
of fatal cases (Supplementary Table 1); none had evidence of bacterial pneumonia, whereas 
6 (60%) had an interstitial pneumonia pattern, of which 5 had a pathological finding of giant 
cell viral pneumonitis consistent with primary measles pneumonia (Figure 3). Two of 6 
postmortem lung tissue specimens that were positive for measles RNA were positive for 
influenza B virus by RT-PCR.
DISCUSSION
During a response to the largest measles outbreak in any postelimination setting, we 
confirmed a significant increase in CFR during outbreak and identified nosocomial measles 
infections among infants diagnosed with influenza or pneumonia as a risk factor for measles 
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death among infants hospitalized for measles. Incidence among infants was high during both 
waves of the outbreak despite a high coverage supplemental immunization activity 
conducted during the first wave [14], as infants infected during the second wave of the 
outbreak were too young to be vaccinated during the campaign.
Linkage of national surveillance and vital statistics data allowed for rapid confirmation of 
increased CFR during the outbreak rather than a reporting artifact. Record linkage has been 
implemented during outbreaks to better understand frequencies of complications and deaths 
[15], hospitalizations [16], and the sensitivity of surveillance systems [10]. In addition to the 
use of probabilistic record linkage to verify CFR, our study provides clinical data from 
medical charts for both cases and controls, which supplement epidemiologic descriptions of 
the outbreak [17]. Although the majority of measles deaths were assigned the ICD-10 code 
for measles, approximately 10% had a nonspecific pneumonia ICD-10 code, suggesting that 
analysis of vital statistics data to determine under-5 mortality alone might result in 
underascertainment of the measles mortality burden [3].
Epidemiologic evidence from our study suggested mortality was associated with nosocomial 
measles virus transmission among infants with preexisting pneumonia or influenza 
diagnoses, and hospitalization outside of the capital city. Nosocomial transmission has been 
increasingly recognized as a barrier to measles elimination in low-incidence settings and has 
been attributed to the high basic reproduction number of the disease and the ability of 
measles virus to remain viable in aerosol suspension for up to 2 hours [18, 19]. HAI was 
found to be a risk factor for infection during the first wave of the outbreak [20] and might be 
more severe than community-acquired infections, as patients have underlying illnesses and 
might be subject to intense virus exposure in a closed setting [18, 21]. Health care workers 
might be at higher risk for measles infection than persons in the community, and 
transmission in health care facilities poses substantial risks to infants and 
immunocompromised persons [22, 23]. WHO recommends that all health care workers be 
measles immune, and proof of vaccination or immunity should be a condition of enrollment 
into training or employment [23]. Infection control measures should be implemented to 
prevent nosocomial measles virus transmission, which include rapid evaluation and 
respiratory isolation of patients with suspected or confirmed measles infection and use of 
respiratory protection, eye protection, gloves, and appropriate hand washing by health care 
workers [19]. An investigation of nosocomial infections during the outbreak identified at 
least 55 measles infections among health care workers during the outbreak [24]. Although 
policies for infection control were available in Mongolia, infrastructure limitations and the 
high number of cases did not allow for their full implementation [24].
Hospitalization for pneumonia or influenza diagnoses during the measles incubation period 
was associated with measles death, suggesting that infants were hospitalized for respiratory 
illnesses prior to measles infection. Although influenza testing was not routinely performed, 
epidemiologic evidence of the circulation of influenza B during the second wave of the 
outbreak and laboratory data suggest a possible mechanism of sequential influenza B and 
measles virus infections increasing measles mortality among infants. Among 10 infants with 
pathologic specimens available, none had evidence of bacterial pneumonia, whereas 
influenza B viral RNA was detected in postmortem specimens from 2 of 6 fatal measles 
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cases that were also positive for measles virus RNA. Coinfection with other respiratory 
pathogens has been associated with increased severity of measles [25]. Although influenza 
and measles coinfections have been previously observed, to our knowledge, this is the first 
study to suggest that previous influenza infection might increase measles fatality. Because 
measles deaths are defined as deaths due to any related cause (ie, including due to influenza 
or pneumonia) [9], and measles is known to produce long-term immune modulation and 
increase mortality from other infectious causes [26], it is possible that some of these measles 
infections were a “second hit” for previously ill infants with preexisting severe respiratory 
infections. Although we cannot conclusively determine whether measles-related 
immunodeficiency increased the risk of death among patients with preexisting lung infection 
or whether preexisting lung infection increased the risk of measles mortality, pathologic 
evidence from 5 fatal measles cases consistent with primary measles pneumonia is 
suggestive of measles being the proximal cause of deaths among these patients. Prevention 
of other respiratory infections, including vaccine-preventable bacterial and viral causes, 
might reduce the morbidity and mortality observed during measles outbreaks.
Only a minority of infants received appropriate vitamin A supplementation. Vitamin A is an 
essential nutrient that regulates human immune function [27]. Vitamin A supplementation 
among children <5 years of age significantly reduces child measles morbidity and mortality 
[28], and is recommended by WHO on 2 consecutive days (at the time of diagnosis and on 
the following day) for all children <5 years of age when measles CFR >1%, in areas of 
known vitamin A deficiency, and as part of case management for suspected measles cases 
[29, 30]. Our finding of an association between anemia and rickets diagnosis with measles 
mortality, conditions not previously known to be associated with measles death, might have 
represented a proxy for vitamin A or other micronutrient deficiencies, as these conditions are 
known to be associated with underlying micronutrient deficiencies [31, 32].
The interpretation of these results is subject to several limitations. First, we were unable to 
directly test the hypothesis that influenza coinfection was more prevalent in fatal cases 
because influenza testing results were not documented; the lack of documentation of 
influenza testing results also limited our ability to distinguish between influenza and viral or 
bacterial pneumonias. Second, interpreting pneumonia etiology (ie, viral coinfection, 
measles pneumonia, or bacterial pneumonia) was limited by the small number of pathologic 
specimens available among fatal cases. Because of the potentially long interval between 
influenza B infection and measles death, it is possible that the pathologic specimens we 
tested underestimated the number of infant measles deaths with influenza B coinfection. We 
were unable to directly measure micronutrient deficiencies, including vitamin A, which 
might be associated with measles mortality, but are associated with 2 covariates in the model 
(rickets and anemia), which resulted in potentially spurious associations between these 
conditions and measles mortality. Last, because we restricted the case control sample to 
infants hospitalized with measles infection during the second wave, we were unable to make 
inferences about other age groups, or other seasonal factors including the severe winter in 
Mongolia (known as Dzud) that occurred during the period of study. Similarly, as medical 
record abstraction was used to obtain data for the study, other social determinants of health 
could not be measured as potential risk factors for mortality.
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This investigation, which took place during a large outbreak, highlighted factors that might 
aid in future outbreak response in postelimination settings. Strong vital registration systems 
can aid in verifying mortality. Prevention of measles HAI might decrease mortality. 
Implementation of national strategies for health care facilities, including appropriate 
infection prevention and control measures, vitamin A supplementation, and adequate 
respiratory support, are critical to reduce mortality from this preventable illness.
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Figure 1. 
Flow diagram of infant measles mortality case-control study population and sample. The 
study population was infant measles cases with laboratory evidence of measles infection 
(positive measles-specific immunoglobulin M antibody or polymerase chain reaction) or 
clinical evidence of measles infection (fever and rash with 1 of cough, coryza, or 
conjunctivitis) during the second outbreak phase (rash onset after 1 October 2015), admitted 
to a hospital from which we could obtain medical records. Fatal measles case patients 
(measles-related deaths) were matched 3:1 on age and date of birth with nonfatal measles 
control patients.
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Figure 2. 
Descriptive epidemiology of Mongolia measles outbreak. A, Epidemiologic curve of 
measles cases by date of rash onset and age category (infants <12 months, black; children 12 
months–14 years, dark grey; adults ≥15 years, light grey). B, Epidemiologic curve of 
measles cases by date of rash onset and residence: Aimags (provinces), black; Ulaanbaatar 
(capital city), grey. C, Epidemiologic curve of health care-associated measles infections (ie, 
hospitalized during 7–21 days before rash onset) by date of rash onset. D, Epidemiologic 
curve of reported measles deaths by date of rash onset. E, Trend of infant hospitalizations for 
influenza-like illness by epidemiologic week.
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Figure 3. 
Hematoxylin and eosin stained specimens of lung tissue from 2 fatal measles cases. A, 
Interstitial pneumonia pattern with Hecht’s giant cells in a fatal measles patient that was 
hospitalized during the measles incubation period, but for a diagnosis other than pneumonia 
or influenza (×20). B, Specimen from the same patient as in (A), at ×40, with Hecht’s giant 
cells. C, interstitial pneumonia pattern without Hecht’s giant cells in a fatal measles patient 
that was hospitalized during the measles incubation period for influenza.
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Table 3.
Multivariable Conditional Logistic Regression for Measles Mortality Among Fatal Measles Cases and 
Matched Nonfatal Measles Controls, Mongolia, 2015–2016
Characteristics Bivariatea OR (95% CI) Adjustedb OR (95% CI)
Infant medical and vaccination history
Received ≥1 dose of vaccine:
 MCVc 2.9 (.8–10.4) 7.1 (.9–58.2)
 Hib/pentavalentd 0.4 (.2–.7) 0.9 (.4–2.0)
Underlying medical conditions
 Premature birth or birth defect 2.3 (1.0–5.0) 4.8 (1.5–15.2)
 Immune deficiency 2.3 (1.1–4.8) 3.6 (1.1–11.3)
 Rickets 9.2 (3.9–21.7) 5.5 (1.7–17.1)
 Malnutritione 3.1 (1.3–7.4) 0.7 (.2–3.5)
 Anemia 15.1 (7.2–31.7) 12.3 (4.9–31.1)
Health care-associated infection
Admitted to hospital 7–21 days before rash onset
 No (non-HAI) REF REF
 HAI: pneumonia or influenza diagnosis 4.5 (2.6–8.0) 4.5 (1.9–10.8)
 HAI: other diagnosisf 1.1 (.4–2.7) 0.7 (.2–2.7)
Health care exposures after rash onset
Location of first hospitalization after rash onset
 Ulaanbaatar REF REF
 Outside of Ulaanbaatar 2.7 (1.6–4.6) 2.4 (1.1–5.8)
Treatment received
 Received vitamin A (any) 0.6 (.3–1.2) 0.5 (.2–1.3)
 Received antibiotics (any) 0.2 (.0–.8) 0.2 (.0–1.7)
Abbreviations: CI, confidence interval; HAI, health care-associated infection; MCV, measles-containing vaccine; OR, odds ratio; REF, reference.
Bold indicates P value <0.05 in the conditional logistic regression model.
aConditional logistic regression OR accounting for matching on age and sex.
bConditional logistic regression OR accounting for matching on age, sex, and controlling for all other variables in Table 3.
c
First dose of MCV at 9 months of age.
d
First dose at 2 months of age.
e2006 WHO Growth Curve Z-score for weight for age less than −2 at the time of first hospital admission after rash onset or chart diagnosis of 
malnutrition.
f
Diarrhea, bronchitis, laryngitis, seizure, meningitis, urinary infection, other.
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Table 4.
Clinical and Diagnostic Findings Among Fatal Measles Cases and Nonfatal Measles Controls, Mongolia, 
2015–2016
Findings Cases, n (%) (n = 95) Controls, n (%) (n = 273)
Pneumonia 91 (95.8) 182 (66.7)
 Acute respiratory distress syndrome 19 (20.0) 1 (0.4)
Chest radiograph findings
 Bilateral consolidation 53 (55.8) 101 (37.0)
 Interstitial pattern 13 (13.7) 61 (22.3)
 None performed 36 (37.9) 105 (38.5)
Neurologic complications 52 (54.7) 52 (19.1)
 Encephalitis 8 (8.4) 0 (0.0)
 Meningitis 4 (4.2) 1 (0.4)
 Seizure 52 (54.7) 52 (19.1)
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